

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-00	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO <b>MXI-101CPACN</b>	SERIAL NO. <b>10/627307</b>
PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT <b>van de Winkel, J.G.J.</b>	
FILING DATE <b>July 25, 2003</b>		GROUP <del>3763</del> <b>1644</b>	

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS
PV	A1	4,470,925	09/84	Auditore-Hargreaves	<del>200</del>	<del>142 B</del>
	A2	4,676,980	06/87	Segal et al.	<del>424</del>	<del>05</del>
	A3	4,954,617	09/90	Fanger et al.	<del>530</del>	<del>387</del>
	A4	5,635,600	06/97	Fanger et al.	<del>530</del>	<del>387.3</del>
V	A5	5,767,106	06/98	Turley et al.	<del>514</del>	<del>54</del>

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
PV	A6	WO 91/00360	01/91	PCT			
	A7	WO 91/03493	03/91	PCT			
	A8	WO 91/05871	05/91	PCT			
	A9	WO 92/05793	04/92	PCT			
	A10	WO 94/10332	05/94	PCT			
V	A11	WO 95/09002	04/95	PCT			

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

PV	A12	Andrews, R. et al. (1986) "The L4F3 Antigen is Expressed by Unipotent and Multipotent Colony-Forming Cells but Not by Their Precursors", <i>Blood</i> , <u>68</u> (5):1030-1035;			
	A13	Ball, E. et al. (1992) "Initial Trial of Bispecific Antibody-Mediated Immunotherapy of CD15-Bearing Tumors: Cytotoxicity of Human Tumor Cells Using a Bispecific Antibody Comprised of Anti-CD15 (MoAb PM81) and Anti-CD64/FcγRI (MoAb 32)" <i>Journal of Hematotherapy</i> <u>1</u> :85-94;			
	A14	Brennan, M. et al. (1985) "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G <sub>1</sub> Fragments" <i>Science</i> <u>229</u> : 81-83;			
	A15	Cuttitta, F. et al. (1981) "Monoclonal Antibodies that Demonstrate Specificity for Several Types of Human Lung Cancer", <i>PNAS</i> , <u>78</u> (7):4591-4595;			
	A16	Graziano, R. et al. (1995) "Construction and Characterization of a Humanized Anti-Gamma-Ig Receptor Type I (FcγRI) Monoclonal Antibody" <i>The Journal of Immunology</i> , <u>155</u> (10):4996-5002;			
	A17	Guyre, P. et al. (1989) "Monoclonal Antibodies that Bind to Distinct Epitopes on FcγRI are Able to Trigger Receptor Function" <i>The Journal of Immunology</i> <u>143</u> (5):1650-1655;			
	A18	Guyre, P. et al. (1983) "Recombinant Immune Interferon Increases Immunoglobulin G Fc Receptors on Cultured Human Mononuclear Phagocytes" <i>Journal of Clinical Investigation</i> <u>72</u> :393-397;			
V	A19	Harris, W. et al. (1993) "Therapeutic Antibodies - The Coming of Age" <i>Tibtech</i> <u>11</u> :42-44;			
Examiner		/F. Pierre Vandervegt/	Date Considered	06/21/2006	
EXAMINER		Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO <b>MXI-101CPACN</b>	SERIAL NO. <b>10/627307</b>
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT <b>van de Winkel, J.G.J.</b>	
		FILED DATE <b>July 25, 2003</b>	GROUP <del>3763</del> <b>1644</b>

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
PV	B1	WO 95/09917	04/95	PCT				
	B2	WO 96/40789	12/96	PCT				
	B3	WO 97/07218	02/97	PCT				
V	B4	WO 98/09647	03/98	PCT				

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

PV	B5	Heijnen, I.A.F.M. and van de Winkel, J.G.J. (1995) "A Human FcγRI/CD64 Transgenic Model for In Vivo Analysis of (Bispecific) Antibody Therapeutics" <i>Journal of Hematotherapy</i> 4:351-356;
	B6	Hird, V. et al. (1990) "Immunotherapy with Monoclonal Antibodies", <i>Genes and Cancer</i> , Edited by D. Carney and K. Sikora, Chapter 17, pp. 183-189;
	B7	Kaminski, N.E. et al. (1986) "Target Ricin by Coupling to an Anti-macrophage Monoclonal Antibody" <i>Journal of Immunopharmacology</i> 8(1):15-37;
	B8	Karpovsky, B. et al. (1984) "Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fcγ Receptor Antibodies" <i>Journal of Experimental Medicine</i> 160:1686-1701;
	B9	Liu, M. et al. (1985) "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes" <i>PNAS</i> 82:8648-8652;
	B10	Schlom, J. (1991) "Monoclonal Antibodies: They're More and Less Than You Think", <i>Molecular Foundations of Biology</i> Edited by Williams and Wilkins, Chapter 6, pp. 95-134;
	B11	Seaver, S. (1994) "Monoclonal Antibodies in Industry: More Difficult Than Originally Thought" <i>Genetic Engineering</i> 14(14):10 & 21;
	B12	Shen, L. et al. (1986) "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG Mediates Cytotoxicity by Human Monocytes that is Enhanced by Interferon-γ and is not Blocked by Human IgG", <i>The Journal of Immunology</i> 137 (11):3378-3382;
	B13	Valerius, T. et al. (December 1997) "FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy" <i>Blood</i> 90(11):4485-4492;
	B14	Valerius, T. et al. (1997) "HLA Class II Antibodies Recruit G-CSF Activated Neutrophils for Treatment of B Cell Malignancies" <i>Leukemia and Lymphoma</i> 26:261-269;
	B15	van de Winkel, J.G.J. et al. (1987) "Characterization of Two Fc Receptors for Mouse Immunoglobulins on Human Monocytes and Cell Lines" <i>Scand. J. Immunol.</i> 26:663-672;
V	B16	van der Pol, W.-Ludo and van de Winkel, J.G.J. (1998) "IgG Receptor Polymorphisms: Risk Factors for Disease" <i>Immunogenetics</i> 48:222-232;
Examiner <b>/F. Pierre Vandervegt/</b>		Date Considered <b>06/21/2006</b>
*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO <b>MXI-101CPACN</b>	SERIAL NO. <b>10/627307</b>
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT <b>van de Winkel, J.G.J.</b>	
		FILING DATE <b>July 25, 2003</b>	GROUP <del>3709</del> <b>1644</b>

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

PV	C1	van Vugt, M.J. et al. (1998) "FcγRII-γ-Chain Complexes Trigger Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in CD5+ B Cell/Macrophage IIA1.6 Cells" <i>Clin. Exp. Immunol.</i> 113:415-422;
	C2	van Vuuren, A.J.H. et al. (June 1999) "Characterization of the Human Myeloid IgA Fc Receptor I (CD89) Gene in a Cosmid Clone" <i>Immunogenetics</i> 49(6):586-589;
	C3	van Zandbergen, G. et al. (Dec. 1998) "Reduced Binding of Immunoglobulin A (IgA) from Patients with Primary IgA Nephropathy to the Myeloid IgA Fc-receptor, CD89" <i>Nephrol. Dial. Transplant.</i> 13(12):3058-3064;
	C4	Würfle, D. et al. (July 1998) "Evaluating Antibodies for Their Capacity to Induce Cell-mediated Lysis of Malignant B Cells" <i>Cancer Research</i> 58:3051-3058;
	C5	Deo, Y.M. et al. (March 1997) "Clinical Significance of IgG Fc Receptors and FcγR-Directed Immunotherapies" <i>Immunology Today</i> 18(3):127-135;
	C6	Garnett, M.C. et al. (1983) "Preparation and Properties of a Drug-Carrier-Antibody Conjugate Showing Selective Antibody-Directed Cytotoxicity <i>In Vitro</i> " <i>Int. J. Cancer</i> 31:661-670 (1983);
✓	C7	Heijnen, I.A.F.M. et al. (January 1996) "Antigen Targeting to Myeloid-specific Human FcγRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice" <i>J. Clin. Invest.</i> 97(2):331-338.
Examiner	/F. Pierre Vandervegt/	
Date Considered	06/21/2006	
*EXAMINER	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO <b>MXI-101CPACN</b>	SERIAL NO. <b>10/627307</b>
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT <b>van de Winkel, J.G.J.</b>	
		FILING DATE <b>July 25, 2003</b>	GROUP <del>3703</del> <b>1644</b>

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>PV</b>	D1	4,671,958	06/87	Rodwell et al.	<del>424</del>	<del>1.53</del>	
	D2	4,869,903	09/89	Lifson et al.	<del>424</del>	<del>195.45</del>	
	D3	5,026,557	06/91	Estis et al.	<del>424</del>	<del>450</del>	
	D4	5,489,525	02/96	Pastan	<del>435</del>	<del>7.23</del>	
	D5	5,578,706	11/96	Ghetie et al.	<del>530</del>	<del>391.7</del>	
	D6	5,580,715	12/96	McGrath et al.	<del>435</del>	<del>3</del>	
	D7	5,658,568	08/97	Bagshawe et al.	<del>424</del>	<del>434.4</del>	
	D8	5,686,072	11/97	Uhr et al.	<del>424</del>	<del>400.1</del>	
<b>V</b>	D9	5,840,840	11/98	Rybak et al.	<del>530</del>	<del>350</del>	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

<b>PV</b>	D10	Bjerke et al. "Fc gamma-receptors in skin and serum from patients with psoriasis, before and after therapy." <i>Acta Derm Venereol Suppl</i> (Stockh). 1994;186:141-2
	D11	Curnow "Clinical experience with CD64-directed immunotherapy. An overview." <i>Cancer Immunol Immunother.</i> 1997 Nov-Dec;45(3-4):210-5
<b>V</b>	D12	Ericson et al. "Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes." <i>Br J Haematol.</i> 1996 Mar;92(3):718-24
Examiner		Date Considered
/F. Pierre Vandervegt/		06/21/2006
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		